We’re improving your experience!

×

Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.

Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.

Stay tuned for these updates, and thank you for being part of our community!

Disease Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:299
Name adenocarcinoma
Definition A carcinoma that has_material_basis_in abnormally proliferating cells, derives_from epithelial cells, which originate in glandular tissue.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer cell type cancer carcinoma adenocarcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00720785 Phase I Bortezomib Natural Killer Cells and Bortezomib to Treat Cancer Completed USA 0
NCT02789228 Phase I MultiTAA-specific T cells Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST) Active, not recruiting USA 0
NCT03391973 Phase II Pembrolizumab Pembrolizumab in Patients With Poor-Prognosis Carcinoma of Unknown Primary Site (CUP) (CUP) Active, not recruiting CAN 0
NCT03396471 Phase II Pembrolizumab Study of Pembrolizumab and Concurrent Radiation in Patients With Previously Treated Carcinoma of Unknown Primary Terminated USA 0
NCT04131621 Phase II Nivolumab Ipilimumab Ipilimumab + Nivolumab Nivolumab/Ipilimumab in Second Line CUP-syndrome (CheCUP) Unknown status DEU 0
NCT04214418 Phase Ib/II Atezolizumab + Cobimetinib + Hydroxychloroquine Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO) Terminated USA 0
NCT04666688 Phase Ib/II LYT-200 LYT-200 + unspecified PD-1 antibody Gemcitabine + LYT-200 + Nab-paclitaxel LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors Completed USA 0
NCT05101356 Phase Ib/II LabVax 3(22)-23 + Sargramostim LabVax 3(22)-23 + Pembrolizumab + Sargramostim A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF Alone or in Combination With Pembrolizumab for the Treatment of Advanced Stage Adenocarcinoma Recruiting USA 0
NCT05165433 Phase I NG-350A + Pembrolizumab Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) (FORTIFY) Active, not recruiting USA | GBR 0
NCT05808634 Phase I BA3182 Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. Recruiting USA 0